Larimar Therapeutics Announces FDA Recommendations On Safety Database And Sets Q2 2026 Nomlabofusp BLA Submission For Friedreich's Ataxia

LARIMAR THERAPEUTICS INC +11.22% Pre

LARIMAR THERAPEUTICS INC

LRMR

0.00

  • Interactions with FDA over the past year have provided clear expectations for the path to submission of the nomlabofusp BLA
  • Written FDA recommendations for safety database include a total of at least 30 participants with continuous exposure for 6 months including a subset of at least 10 with 1-year; large majority of the exposure should be on the 50 mg dose
  • BLA submission seeking accelerated approval planned in the second quarter of 2026 to allow for inclusion of the recommended safety data for adults and children
  • OLE data expected in September 2025 from 30-40 participants who received at least one dose of nomlabofusp; data will include participants on the 50 mg dose
  • Adolescent PK run-in data expected in September 2025 from 14 participants (some on placebo); participants currently screening and enrolling into OLE
  • Global Phase 3 study activities are ongoing with identification and qualification of sites in U.S., Europe, U.K., Canada, and Australia
  • Company management to host webcast and conference call today at 8:00 a.m. ET
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via